TELA described clinician testimony that Ovatex helped a severe pancreatitis patient decompress within one to two weeks, enabled complete abdominal wall closure, and was followed by no recurrent hernia.
TELA · TELA Bio, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Nov 10, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
TELA Bio, Inc. plans to offer up to $150,000,000 of common stock, preferred stock, debt securities, warrants, units and subscription rights. The replacement shelf also covers $90,942,963.70 of unsold securities previously registered before the November 20, 2026 expiration.
TELA Bio's quarterly revenue fell 8% to $19.0 million and net loss rose 8% to $9.3 million. It implemented cost actions targeting approximately $17.0 million in annual operating-expense reductions through a targeted headcount reduction of approximately 20%.
TELA Bio reported third-quarter 2026 revenue of $19.0 million, down 8% from the prior-year period, while a $17.0 million cost-reduction initiative extends cash runway into 2028. Adjusted EBITDA loss improved 39% to $3.4 million, and cash totaled $22.7 million.
On October 8, 2026, TELA Bio, Inc. stockholders approved an amendment authorizing a reverse stock split. The company said it does not intend to effect the split after regaining Nasdaq compliance on October 5, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 10, 2026TL;DR. International and US hernia revenue growth, lower operating and adjusted EBITDA losses, cost reductions, Nasdaq compliance, 510(k) clearance, favorable clinical results, and market-share gains were positive developments. Revenue and gross margin declined year over year, GAAP net loss widened, interest expense increased, and the company ended the quarter with $22.7 million of cash, current debt of 56,299 (in thousands), and a stockholders' deficit of 24,576 (in thousands).
- − Third-quarter revenue decreased 8% year over year, primarily because of lower OviTex PRS volumes.
- − Gross margin declined to 64.9% from 67.5%, primarily because of a higher excess-and-obsolete-inventory charge.
- − GAAP net loss widened to $9.3 million from $8.6 million.
- − Interest expense increased year over year from 1,201 to 2,099 (in thousands).
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| OviTex PRS units sold | 1,050 | the three months ended June 30, 2026 filing | — |
| OviTex units sold | 5,776 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TELA
this stock
TELA Bio, Inc.
|
$37.06M | -30.5% | +15.8% | — | 1.3% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 25
TELA Bio reported third-quarter 2026 revenue of $19.0 million, down 8% from the prior-year period, while a $17.0 million cost-reduction initiative extends cash runway into 2028. Adjusted EBITDA loss improved 39% to $3.4 million, and cash totaled $22.7 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TELA | +0.0% | -15.9% | +0.8% | +1.2% | -30.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -2.6% | -14.7% | +0.3% | +1.4% | -41.1% |